Immunomedics (IMMU) Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma
Tweet Send to a Friend
Immunomedics, Inc. (Nasdaq: IMMU) announced that epratuzumab labeled with the potent radioisotope, yttrium-90 (Y-90) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
